Can acupuncture soothe Chemo's nerve pain? small study hints yes
NCT ID NCT02129686
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested whether acupuncture could reduce tingling, numbness, and pain in the hands and feet caused by chemotherapy in breast cancer survivors. Fifty-seven women who had completed taxane-based chemotherapy were randomly assigned to receive acupuncture immediately or after a delay. The study measured changes in neuropathy symptoms using a questionnaire. Results may help design larger trials to confirm if acupuncture is a useful supportive therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- acupuncture
- What this could lead to
- If it works, this could offer a drug-free way to manage nerve pain after chemotherapy for breast cancer.
- What could go wrong
- This is a small pilot study with only 57 participants, so results may not apply to everyone. Acupuncture's effects can vary, and the study didn't compare against a sham or placebo group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
57 people
The number who actually took part.
- Started
-
Jun 2014
- Finished
-
Jun 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * History of histologically or cytologically proven breast cancer at stage I, II and III, without evidence of distant metastasis; * Completed adjuvant taxane-based chemotherapy as single agents or in combination with platins or HER-2 directed therapy * Reporting grade 1 or greater of the following symptoms persistently for more than 2 weeks: neuropathic pain, allodynia, areflexia, dysesthesia, paresthesia, hyperesthesia, hypoesthesia or glove and stocking syndrome as defined by Common Terminology Criteria for Adverse Events (CTCAE v. 4.03) (Table 1 and the screening checklist); * Patients who are currently on stable prescription medications or dietary supplements for CIPN and still symptomatic as defined above will be allowed to participate in the study. Related medications are: gabapentin, pregabalin, nortriptyline, amitriptyline, duloxetine, venlafaxine; lidocaine, opioid tramadol and other narcotics; NSAIDs; glutamine, glutathione, vitamin E and vitamin B12; * Age ≥ 18 years; * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; * Adequate hematological function: neutrophil count \>1.0 x109/L, platelet count \>50x109/L; * Signed informed consent. Exclusion Criteria: * Patients with any of the following criteria will not be eligible for the study: * Unstable cardiac disease or myocardial infarction within 6 months prior to study entry; * Wearing a pacemaker or implantable cardioverter-defibrillator; uncontrolled seizure disorder; * History of pre-existing peripheral neuropathy prior to chemotherapy, including alcoholism, vitamin B deficiency, diabetes, HIV, congenital neuropathy, toxic neuropathy; * Peripheral neuropathy caused by tumor infiltration or compression of spinal nerves or surgical trauma; * Pregnancy or potential pregnancy and nursing; * Active clinically significant uncontrolled infection; * Prior use of acupuncture for CIPN within 6 months prior to study entry; * Patients with uncontrolled major psychiatric disorders, such as major depression or psychosis, will not be eligible for this trial. Patients with a history of depression or anxiety who are stable on or off psychiatric medications will be eligible.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chemotherapy induced peripheral neuropathy (CIPN) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ozone gas ease Chemo's lasting numbness?
- Can a Five-Session therapy ease distress and calm stress biology in Late-Stage breast cancer?
- One shot of radiation: can a single dose replace weeks of breast cancer treatment?
- Your genes may decide if breast cancer drug causes joint pain
- Chilling out Chemo's side effects: could cold therapy shield nerves?
- Could simple exercises rebuild strength after chemotherapy nerve damage?